Patents Examined by Jia-Hai Lee
  • Patent number: 10525107
    Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 7, 2020
    Assignee: Alkahest, Inc.
    Inventors: David Bell, Ian Gallager, Steven P. Braithwaite, S. Sakura Minami, Vu Dang, Joe McCracken, Karoly Nikolich
  • Patent number: 10512695
    Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises inulin.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: December 24, 2019
    Assignee: FERRING B.V.
    Inventors: Varinder Ahuja, Tejas Gunjikar, Kristin Wannerberger
  • Patent number: 10500287
    Abstract: The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine residues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amphipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 10, 2019
    Assignee: The Queen's University of Belfast
    Inventors: Helen McCarthy, Aleksey Zholobenko, Ashley Davison, Tracy Robson
  • Patent number: 10487115
    Abstract: Disclosed are proteinaceous molecules and their use in conditions associated with PKC-? overexpression, such as cancer. More particularly, the present invention discloses proteinaceous molecules and their use in altering at least one of (i) formation; (ii) proliferation; (iii) maintenance; (iv) epithelial to mesenchymal cell transition; or (v) mesenchymal to epithelial cell transition of a PKC-? overexpressing cell.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: November 26, 2019
    Assignee: UNIVERSITY OF CANBERRA
    Inventors: Sudha Rao, Peter Milburn
  • Patent number: 10487121
    Abstract: Disclosed are D-peptide compositions and methods for inhibiting HIV entry into host cells.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 26, 2019
    Assignees: Navigen, Inc., University of Utah Research Foundation
    Inventors: Brett D. Welch, James Nicholas Francis, Michael S. Kay
  • Patent number: 10478470
    Abstract: The present invention relates to a pharmaceutical composition containing leuprolide acetate and having both immediate and sustained release properties and, more specifically, to a pharmaceutical composition in which, on the basis of the total weight of active ingredients, leuprolide as an immediate release preparation is contained in 0.001 wt % to 25 wt %; and leuprolide contained in microspheres of a sustained release preparation is contained in 75 wt % to 99.999 wt %. The pharmaceutical composition of the present invention is characterized by satisfying both a drug immediate release property so as to realize the prompt exposure to a sufficient amount of drug at the early stage for expression of medicinal effects and a drug sustained release property for four weeks or longer, and the pharmaceutical composition is effective in the prevention and treatment of sex hormone-dependent positive or malignant diseases.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 19, 2019
    Assignee: SK CHEMICALS CO., LTD.
    Inventors: Hong Kee Kim, Kyu Ho Lee, Seok Hyun Hong, Yong-kyu Kwak, Ho Chul Shin, Hun-Teak Kim
  • Patent number: 10464968
    Abstract: The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralising a tooth lesion such as a subsurface caries lesion.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: November 5, 2019
    Assignee: Credentis AG
    Inventors: Michael Hug, Dominikus Amadeus Lysek
  • Patent number: 10457716
    Abstract: The instant disclosure provides a microscale method for providing correctly folded, and assembled biologically active proteins in an efficient and shorted time frame, compared to conventional protein production techniques. Proteins produced from inclusion bodies and other aggregated protein sources are provided. Microscale production of correctly folded and assembled class I MHC protein and complexes thereof are also provided for, as well as for high throughput production for use in epitope discovery protocols. Microscale production of complex proteins from protein aggregates and preparations containing protein aggregates is provided that requires less than 24 hours of processing time.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: October 29, 2019
    Assignee: University of Notre Dame du Lac
    Inventors: Brian M Baker, Lance Hellman
  • Patent number: 10442835
    Abstract: The present invention relates to technical fields of organic chemistry and pharmaceutical chemistry, specifically to water-soluble rapamycin derivatives modified with glutathione. More specifically, the present invention discloses a compound of formula I and the preparation method thereof, wherein R1 and R2 are as defined in the description. The compound of formula I can be used in inducing immunosuppression and in the treatment of diseases such as transplant rejection and solid tumor, etc.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: October 15, 2019
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Haibo Wang, Hongfu Kuang, Wei Zhang, Zhengjiang Cai, Tianmin Zhu, Xiaohe Zheng, Zhongwei Wu, Zhiqing Yang
  • Patent number: 10435434
    Abstract: Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: October 8, 2019
    Assignee: ENB THERAPEUTICS, INC.
    Inventor: Sumayah Jamal
  • Patent number: 10426817
    Abstract: The present disclosure provides apolipoprotein (apo) mimetics useful for the treatment of age-related macular degeneration (AMD) and other eye disorders. The apo mimetics can be peptides/polypeptides that mimic, e.g., the lipid-clearing action of apolipoproteins such as apoA-I and apoE. The apo mimetics can exert other beneficial effects, such as reduction of inflammation, oxidative stress and neovascularization. The apo mimetics can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (GA) (including non-central GA and central GA) and neovascularization (NV) (including types 1, 2 and 3 NV). The apo mimetics can be used alone or in conjunction with other therapeutic agents, such as a complement inhibitor and/or an anti-angiogenic agent, to treat AMD, including atrophic AMD and neovascular AMD, and other eye disorders.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 1, 2019
    Assignee: MacRegen, Inc.
    Inventors: Martin Rudolf, Keith Roizman
  • Patent number: 10426850
    Abstract: The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Zm-[Gly-X-Y]n-LGly-X-Y-[Gly-X-Y]n (SEQ ID NO: 19); wherein L is one or more detectable moieties; S is one or more spacer molecules; Zm is any amino acid where m is an integer of 1 to 10; X is proline or modified proline; Y is proline or modified proline; Gly is glycine; n is an integer from 1 to 20; and LGly is a glycine covalently linked to a cage moiety comprising a labile protecting group, as well as a collagen mimetic peptides lacking the labile protecting group (CMP). The inventions are useful for binding collagen and denatured collagen and/or gelatin both in vitro and in vivo, and are useful for targeting any organ or tissue where collagen is present, and can be used for research and diagnostic imaging (both in vivo and in vitro) and also for in vivo therapeutic applications.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: October 1, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Michael S. Yu, Yang Li, Daniel Summerfield, Allen Yi-Lan Wang, Catherine A. Foss, Martin G. Pomper
  • Patent number: 10420844
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • Patent number: 10391151
    Abstract: In permeability lung edema, cardiogenic lung edema or neonatal respiratory distress, there is heterogeneous liquid distribution throughout the lungs. The excess alveolar liquid reduces gas exchange. Mechanical ventilation is used to improve gas exchange. In the presence of heterogeneous liquid distribution, there are surface tension-dependent stress concentrations in septa separating aerated from flooded alveoli. Mechanical ventilation, by inflating the lung above normal volumes, thus increasing surface tension above normal, exacerbates the stress concentrations and consequently injures, or exacerbates pre-existing injury of, the alveolar-capillary barrier. Any means of lowering surface tension should lessen ventilation injury of the lung. In the present invention, dilute exogenous surfactant solution or surfactant protein C solution interacts with albumin to lower surface tension, likely through effective promotion of surfactant lipid adsorption.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: August 27, 2019
    Assignee: The Trustees of the Stevens Institute of Technology
    Inventor: Carrie E. Perlman
  • Patent number: 10383796
    Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: August 20, 2019
    Assignee: Lubris LLC
    Inventors: Edward R. Truitt, Nicole Barbara Justis Truitt
  • Patent number: 10364269
    Abstract: The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.
    Type: Grant
    Filed: May 21, 2016
    Date of Patent: July 30, 2019
    Assignee: LAURUS LABS LIMITED
    Inventors: Sanjay Kumar Dehury, Nagaraju Mekala, Jahangeer Baba Shaik, Srinivasa Rao Buddepu, Lakshmi Kanth Kola, Venkata Sunil Kumar Indukuri, Seeta Rama Anjaneyulu Gorantla, Satyanarayana Chava
  • Patent number: 10358469
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. In particular, the present invention relates to a polypeptide comprising or consisting of i) an amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, ii) an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1, or iii) an amino acid sequence which is a retro-inverso of the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, iv) an amino acid sequence which is retro-inverso of the amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: July 23, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP)
    Inventors: Jean-Luc Poyet, Heriberto Bruzzoni-Giovanelli, Léonard Jagot-Lacoussiere
  • Patent number: 10351611
    Abstract: According to the embodiments described herein, a series of biological materials for treatment/therapy of DMD and/or BMD through the recovery of sarcolemmal nNOS is provided. The biological material comprises the complete dystrophin repeats R16 and R17 or certain domains, sections, or fragments of the dystrophin repeats R16 and R17. In some aspects, such domains, sections, or fragments may be selected from sequence motifs including dystrophin R17 ?1 helix, ?2 and ?3 helices of both R16 and R17, or a combination thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 16, 2019
    Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Yi Lai, Junling Zhao, Yongping Yue, Dongsheng Duan
  • Patent number: 10350271
    Abstract: Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides towers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: July 16, 2019
    Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I., FYZIOLOGICKY USTAV AKADEMIE VED CR, V.V.I.
    Inventors: Lenka Maletinska, Blanka Zelezna, Jaroslav Kunes, Veronika Prazienkova
  • Patent number: 10344069
    Abstract: The present invention relates to a process for the preparation of Liraglutide, which comprises: a) synthesis of suitable fragments (protected) by solid phase peptide synthesis; b) coupling of the suitable fragments on solid support; c) concurrently cleaving the protected peptide from the solid support and de-protecting the peptide; d) purification of Liraglutide (crude) on reverse phase HPLC; e) isolating pure Liraglutide.
    Type: Grant
    Filed: October 31, 2015
    Date of Patent: July 9, 2019
    Assignee: Auro Peptides Ltd.
    Inventors: Suresh Kumar Vadlamani, Patil Nilesh Dagadu, Mohammed Abdul Shafee, Sanjay Devidas Patil, Nagana Goud Agasaladinni